JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

A Novel Prognostic Signature Integrating Immune and Glycolytic Pathways for Enhanced Prognosis and Immunotherapy Prediction in Hepatocellular Carcinoma

  • 0Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, People's Republic of China.
Journal of Hepatocellular Carcinoma +

|

April 23, 2025

|

April 23, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

This study developed an immune-glycolysis-related prognostic signature (IGRPS) to predict hepatocellular carcinoma (HCC) outcomes. The IGRPS accurately forecasts patient prognosis and response to immunotherapy, aiding treatment strategies.

Area Of Science

  • Oncology
  • Immunology
  • Metabolic pathways

Background

  • Hepatocellular carcinoma (HCC) poses a significant challenge in clinical oncology.
  • Predicting HCC patient prognosis and response to therapy remains complex.
  • Integrating immune and glycolytic factors may offer novel prognostic insights.

Purpose Of The Study

  • To establish an immune-glycolysis-related prognostic signature (IGRPS) for hepatocellular carcinoma (HCC).
  • To evaluate the IGRPS's predictive capability for patient survival and immunotherapy response.
  • To explore the association between the IGRPS and the tumor immune microenvironment (TIME) and glycolytic pathways.

Main Methods

  • Utilized RNA-sequencing and single-cell sequencing data from TCGA and GEO.
  • Employed weighted gene co-expression network analysis (WGCNA) and Cox regression to identify survival-related immune and glycolysis genes (SRIGRGs).
  • Validated the IGRPS using Kaplan-Meier analysis, ROC curves, and prognostic nomograms; assessed in vitro gene function.

Main Results

  • Identified 13 SRIGRGs to construct the IGRPS.
  • The IGRPS demonstrated strong predictive performance (AUC > 0.7) and identified patients with significantly longer survival.
  • Low-risk patients showed improved responses to anti-CTLA4 and anti-PD-1 therapies; in vitro studies confirmed gene roles in HCC progression.

Conclusions

  • The developed IGRPS serves as a robust, independent prognostic biomarker for HCC.
  • IGRPS effectively predicts immunotherapy response in HCC patients.
  • This signature offers valuable insights into the interplay of immunity and glycolysis in HCC progression and treatment.

Keywords: